The FDA acceptance marks the first step in addressing the unmet need for a lasting treatment option for patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Russ Conroy
Advertisement
Articles by Russ Conroy
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Drug Topics
1
The Emergence of CGRP-Targeted Therapies is Transforming Migraine Care | NCPA 2025
2
Meaningful Recognition: What Pharmacy Technicians Really Want on World Pharmacy Technician Day
3
FDA Approves Tezepelumab for as Add-On Treatment for Chronic Rhinosinusitis With Nasal Polyps
4
Pharmacists Improve Patient Health Through Medication Reviews
5
